SEC Tracker
Get the app

Moleculin Biotech MBRX

Moleculin Biotech approves stock plan increase

Form
8-K
Filed
Importance
Routine
  1. Approved 2024 Equity Plan increase by 3,861,894 shares
  2. Ratified Grant Thornton as auditor for 2026
  3. Approved reverse stock split authority
  4. Approved adjournment authority for meeting

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Moleculin Biotech files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. GT Biopharma GTBP public float $9M, Jun 30, 2025
  2. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  3. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  4. Biovie BIVI public float $8M, Dec 31, 2025
  5. Artelo Biosciences ARTL public float $9M, Jun 30, 2025